High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series

Abstract Anaplastic lymphoma kinase (ALK) fusion gene‐positive lung cancer often shows brain metastasis at initial diagnosis or during the course of treatment. However, molecular‐targeted drugs are known to pass through the blood–brain barrier and present positive effects for central nervous system...

Full description

Bibliographic Details

Published in:	Thoracic Cancer
Main Authors:	Kei Morikawa, Yu Numata, Yusuke Shinozaki, Shotaro Kaneko, Aya Matsushima, Makoto Nishida, Hirotaka Kida, Hiroshi Handa, Hiroki Nishine, Masamichi Mineshita
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Subjects:	ALK fusion gene‐positive lung cancer brain metastasis brigatinib non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitors (TKIs)
Online Access:	https://doi.org/10.1111/1759-7714.15207